Aranesp dosed every three weeks achieved and maintained target hemoglobin levels (EurekAlert!)
home > yahoo news
ORLANDO, Fla., (May 15, 2005) ? Amgen Inc., (NASDAQ: AMGN) the world's largest biotechnology company, today announced that new interim data from a single-arm, open label study of 1,225 cancer patients receiving chemotherapy demonstrated that Aranesp® (darbepoetin alfa) administered every three weeks was effective in increasing and maintaining patient hemoglobin levels to the recommended target of
- link to Aranesp dosed every three weeks achieved and maintained target hemoglobin levels (EurekAlert!) -
Last update: 05/26/2005